Latest From Abcam PLC
This week’s roundup includes various high-level appointments by companies including Vencerx Therapeutics, which has elected a new CEO, Shield Therapeutics, Crescendo Biologics, Pluristem Therapeutics, Sarepta Therapeutics and Verona Pharma.
Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.
Another week has seen another plethora of deals between Chinese domestic players and global gene sequencing firms. Rising demand for individualized treatments and the rush for cancer immuno-therapies is propelling fast growth for the US-Chinese biotech company Crownbio, says its executive chairman Guo-Liang Yu.
In a deal worth over $1 billion, Depomed got US rights to Janssen's pain drug Nucynta; Roche bought the majority stake in Foundation Medicine. FOPOs drove a large part of biopharma financing.
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Abcam Ltd.
- Western Europe
- Parent & Subsidiaries
- Abcam PLC
- Senior Management
Alan Hirzel, CEO
Jeff Iliffe, CFO
Jim Warwick, COO
Jonathan Milner, Deputy Chairman
- Contact Info
Phone: (44) (0)1223 696000
330 Cambridge Science Pk.
Cambridge, CB4 0FL
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.